David Amsellem is a managing director and senior research analyst at Piper Sandler covering specialty pharmaceuticals. Prior to joining Piper Sandler in 2008, Amsellem spent five years at Friedman Billings Ramsey, where he was a senior research analyst covering small- and mid-cap pharmaceuticals from 2006-08 and a senior associate on the biotechnology equity research team from 2003-06. Amsellem has more than 15 years of Wall Street experience focused on the biopharmaceuticals space, with experience in life sciences investment and merchant banking prior to moving to the sell-side. Amsellem earned a bachelor’s degree from Cornell University.